This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integer Holdings (ITGR) Q4 Earnings and Sales Beat, Margins Up
by Zacks Equity Research
Integer Holdings (ITGR) reports fourth-quarter results, with earnings and revenues beating their respective consensus marks.
Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
West Pharmaceutical (WST) Beats on Q4 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Masimo's (MASI) MightySat Pulse Oximeter Receives FDA Approval
by Zacks Equity Research
Masimo's (MASI) MightySat Medical Pulse Oximeter receives FDA clearance, which makes it the first FDA-approved pulse oximeter to be available OTC.
Veeva (VEEV) & Boehringer Partner to Boost Animal Healthcare
by Zacks Equity Research
Veeva (VEEV) collaborates with Boehringer to offer its Veeva Vault Clinical and Veeva Vault RIM applications to improve animals??? healthcare via technological upliftment.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Edwards (EW) Gains From Balanced Core Growth and New Launches
by Zacks Equity Research
Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.
Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi
by Zacks Equity Research
Tandem's (TNDM) Mobi is claimed to be the world's smallest durable automated insulin delivery system.
QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall
by Zacks Equity Research
Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.
CVS Health (CVS) Gains From Digital Adoption Amid Competition
by Zacks Equity Research
CVS Health (CVS) has been removing barriers to digital adoption and making it easier for customers to access services such as pharmacy refills and advanced scheduling for immunizations online.
GE Healthcare (GEHC), MedQuest Partner to Boost Imaging Field
by Zacks Equity Research
GE Healthcare (GEHC) collaborates with MedQuest to optimize outpatient imaging networks. With AI capabilities from GE Healthcare, MedQuest is likely to provide better solutions in the imaging space.
ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device
by Zacks Equity Research
ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.
Are Investors Undervaluing HCA Healthcare (HCA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing
by Zacks Equity Research
Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.
Analyzing 3 Healthcare Stocks Poised for Q4 Earnings Beat
by Kaibalya Pravo Dey
Rising patient volumes, admissions, health awareness and technological advancements in the Q4 are likely to have benefited healthcare players like Universal Health (UHS), Alignment Healthcare (ALHC) and Agiliti (AGTI).
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System
by Zacks Equity Research
Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.
DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand
by Zacks Equity Research
Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.
Here's Why You Should Invest in Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.
DexCom (DXCM) Launches One+ Real-time CGM System in Europe
by Zacks Equity Research
DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.
McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
by Zacks Equity Research
Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.
Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
by Zacks Equity Research
Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.
Hologic (HOLX) Introduces Genius Digital Diagnostics System
by Zacks Equity Research
Hologic's (HOLX) Genius Digital Diagnostics System will assist laboratories and healthcare providers with the information needed to make more timely and successful treatment decisions for patients.